In vivo effects of histidine and carnosine against diabetic deterioration in diabetic Balb/cA mice were studied. Histidine and carnosine at 0.5, 1 g/l were added into drinking water. After 4 weeks intake of these agents, the content of histidine and carnosine in plasma, heart and liver significantly elevated ( P<0.05). The intake of these agents significantly decreased plasma glucose and fibronectin levels ( P<0.05); however, only 1 g/l histidine and carnosine treatments significantly increased insulin level ( P<0.05) in diabetic mice. Triglyceride level in heart and liver was dose-dependently reduced by histidine or carnosine treatments ( P<0.05); however, only 1 g/l histidine and carnosine treatments significantly reduced cholesterol level in heart and liver ( P<0.05). The administration of histidine or carnosine significantly enhanced catalase activity and decreased lipid oxidation levels in kidney and liver ( P<0.05); however, only 1 g/l histidine and carnosine treatments significantly increased glutathione peroxidase activity ( P<0.05). The increased interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha in diabetic mice were significantly suppressed by the intake of histidine or carnosine ( P<0.05). In human low density lipoprotein, histidine or carnosine showed dose-dependently suppressive effect in glucose-induced oxidation and glycation ( P<0.05). These data suggest that histidine and carnosine are potential multiple-protective agents for diabetic complications prevention or therapy.